PJA1 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q8NG27 |
---|---|
Clone Names | 100525077 |
Gene ID | 64219 |
---|---|
Other Names | E3 ubiquitin-protein ligase Praja-1, Praja1, 632-, RING finger protein 70, PJA1, RNF70 |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | PJA1 |
---|---|
Synonyms | RNF70 |
Function | Has E2-dependent E3 ubiquitin-protein ligase activity. Ubiquitinates MAGED1 antigen leading to its subsequent degradation by proteasome (By similarity). May be involved in protein sorting. |
Tissue Location | Expressed in various regions of the brain including the cerebellum, cerebral cortex, medulla, occipital pole, frontal lobe, temporal lobe and putamen. Highest levels in the cerebral cortex |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes an enzyme that has E2-dependent E3ubiquitin-protein ligase activity. This enzyme belongs to a classof ubiquitin ligases that include a RING finger motif, and it caninteract with the E2 ubiquitin-conjugating enzyme UbcH5B. This geneis located in an area of chromosome X where several X-linked mentalretardation disorders have been associated, and it has also beenfound as part of a contiguous gene deletion associated withcraniofrontonasal syndrome, though a direct link to any disorderhas yet to be demonstrated. Alternative splicing results inmultiple transcript variants.
References
Wieland, I., et al. Clin. Genet. 72(6):506-516(2007)Saha, T., et al. Oncogene 25(5):693-705(2006)Mishra, L., et al. Cancer Biol. Ther. 4(7):694-699(2005)Sasaki, A., et al. J. Biol. Chem. 277(25):22541-22546(2002)Yu, P., et al. Genomics 79(6):869-874(2002)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.